Continuous Ketone Monitoring: The DKA Prevention Layer Wearables Just Unlocked
Dr. Dereck Mush, MD, MBA
Senseonics
Makes implantable continuous glucose monitors and is studying its investigational Freedom system in people.
What they do
Senseonics (NASDAQ: SENS) sells the Eversense implantable continuous glucose monitor. On October 26, 2026 it initiated a first-in-human study of Freedom, an investigational CGM designed to communicate directly with a mobile device without an external on-body transmitter; Freedom is not approved and its intended features are not clinically established.
The record
- Vertical
- Remote Monitoring & Wearables
- Sub-segment
- Continuous glucose monitoring
- Product type
- Device
- Stage
- Public
- Headquarters
- Germantown, Maryland
- Region
- North America
- Founded
- 1996
- Total funding
- Undisclosed
Also in Remote Monitoring & Wearables
Related on The Signal
Dr. Dereck Mush, MD, MBA
Hardware Tiering and AI Coaching: How Google's Fitbit Edge Reshapes Continuous Monitoring Economics
Dr. Dereck Mush, MD, MBA
Everyone Is Wearing a Glucose Monitor Now. Most of Them Do Not Have Diabetes.
Dr. Dereck Mush, MD, MBAOver-the-Counter Glucose Monitors Put a Clinical Sensor on Healthy People. Now What?
Dr. Dereck Mush, MD, MBA